Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norephedrine is a psychoactive small molecule that acts as an indirect sympathomimetic, primarily by inducing the release of noradrenaline, which leads to increased cardiac contractility and heart rate. It is an amphetamine analogue and a natural constituent of the khat plant (Catha edulis) and Ephedra herba. Norephedrine is also a metabolite of methamphetamine and serves as a pharmaceutical intermediate in the synthesis of other drugs like ephedrine and pseudoephedrine. It has been identified as a critical active ingredient in traditional Chinese medicine (Yangke powder) for alleviating allergic asthma, where it modulates the PI3K/AKT/NF-κB pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norephedrine.